Twenty Years of Autologous Stem Cell Transplantation in Diffuse Large B-Cell Lymphoma: A Single Portuguese Center Experience

Authors

  • Margarida Dantas Brito Bone Marrow Transplantation Service. Instituto Português de Oncologia do Porto. Porto.
  • Fernando Campilho Bone Marrow Transplantation Service. Instituto Português de Oncologia do Porto. Porto.
  • Rosa Branca Bone Marrow Transplantation Service. Instituto Português de Oncologia do Porto. Porto.
  • Carlos Vaz Bone Marrow Transplantation Service. Instituto Português de Oncologia do Porto. Porto.
  • Susana Roncon Celular Therapy Service. Instituto Português de Oncologia do Porto. Porto.
  • António Campos Bone Marrow Transplantation Service. Instituto Português de Oncologia do Porto. Porto.

DOI:

https://doi.org/10.20344/amp.6617

Keywords:

Hematopoietic Stem Cell Transplantation, Lymphoma, Large B-Cell, Diffuse, Transplantation, Autologous.

Abstract

Introduction: Diffuse large B-cell lymphoma can be cured in 60% – 70% of patients. Autologous stem cell transplantation is the standard treatment for relapsed disease. This high-intensity treatment after first complete remission in patients with high International Prognostic Index remains controversial and was performed in our department during some years.
Material and Methods: Retrospective study, review of clinical records.
Results: This study evaluates the outcome of 113 patients transplanted between 1992 and 2012. Considering status before transplantation patients were divided in groups: a) first complete remission after 1 line of chemotherapy (n = 64); b) first complete remission after ≥ two chemotherapy lines (n = 15); c) second complete remission (n = 15); d) more advanced diseased (n = 19). Chemotherapy used in first line therapy was mainly R-CHOP (n = 71) and CHOP (n = 28). The median follow-up of patients still alive was 34 months (1 - 221). At five years, overall survival was 73% (± 5) and disease free survival was 75% (± 5).
Conclusion: Conventional chemotherapy followed by autologous stem cell transplant is a safe and efficient option for selected patients. In our series 70% high-risk patients were free from disease with this strategy.

Downloads

Download data is not yet available.

Downloads

Published

2016-03-31

How to Cite

1.
Brito MD, Campilho F, Branca R, Vaz C, Roncon S, Campos A. Twenty Years of Autologous Stem Cell Transplantation in Diffuse Large B-Cell Lymphoma: A Single Portuguese Center Experience. Acta Med Port [Internet]. 2016 Mar. 31 [cited 2024 Mar. 29];29(3):205-9. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/6617

Issue

Section

Original